Alteration of trabecular bone under chronic beta2 agonists treatment
about
Lack of α2C-Adrenoceptor Results in Contrasting Phenotypes of Long Bones and Vertebra and Prevents the Thyrotoxicosis-Induced OsteopeniaBeta-1 adrenergic agonist treatment mitigates negative changes in cancellous bone microarchitecture and inhibits osteocyte apoptosis during disuse.Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.Beta2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals.Inner Ear Vestibular Signals Regulate Bone Remodeling via the Sympathetic Nervous System.Regulation of bone remodeling by the central and peripheral nervous systemShort term salbutamol ingestion and supramaximal exercise in healthy womenRevisiting the Debate: Does Exercise Build Strong Bones in the Mature and Senescent Skeleton?The Vestibular System: A Newly Identified Regulator of Bone Homeostasis Acting Through the Sympathetic Nervous System.Bone Microarchitecture in Type 1 Diabetes: It Is Complicated.β-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species.Sympathetic denervation-induced MSC mobilization in distraction osteogenesis associates with inhibition of MSC migration and osteogenesis by norepinephrine/adrb3.Assessment of trabecular bone microarchitecture by two different x-ray microcomputed tomographs: a comparative study of the rat distal tibia using Skyscan and Scanco devices.Using the Connectivity Map to discover compounds influencing human osteoblast differentiation.Doping dose of salbutamol and exercise training: impact on the skeleton of ovariectomized rats.Doping dose of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats.Thyroid hormone interacts with the sympathetic nervous system to modulate bone mass and structure in young adult mice.Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation.
P2860
Q27331572-F0574C71-C90A-467C-B460-3D20B609C98EQ34166085-88ADDE7B-2C44-4368-BFF1-27029126E30DQ34837191-ED8CD9F1-B9DD-4FA8-B843-C3A6C4F23317Q35157911-77C54BCC-1C24-4A21-952D-617D913FCE96Q36636110-8D597B09-439D-438C-B5AA-02C34514C61BQ36724983-90A5BE89-8207-438F-BBBB-A67E4CFED542Q36929659-0C0F07F6-1216-46EC-BC1A-5BCB53FC83F9Q37250356-25BC2400-8385-4E47-8877-0037B1EF9192Q38504769-7B94FCA4-04A4-4B6A-9F3F-31354EE2A57EQ38972521-5CF80C16-0679-4217-B2E3-791D0C109F40Q39241378-DFA35985-9609-4371-859B-A3A06F928C2CQ42103326-AC2CD898-123F-4037-AA97-A335EA57CA1DQ45994847-ED51A65A-32EE-4818-BEF2-1E21F58864AEQ47384641-72E86EF5-8C31-4AAF-8B96-540E5EF6E241Q51754302-45327ACF-6CBC-484D-BBFB-80C822EA4610Q51772800-D12B5924-285B-4453-9EB7-88864B1914B7Q53036168-CE132B48-0611-49EB-8944-CE8122A81847Q53753971-20F155C0-B5EB-47B1-B757-6BC56DD13F80
P2860
Alteration of trabecular bone under chronic beta2 agonists treatment
description
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2005
@ast
scientific journal article
@en
wetenschappelijk artikel (gepubliceerd op 2005/09/01)
@nl
наукова стаття, опублікована у вересні 2005
@uk
مقالة علمية (نشرت في سبتمبر 2005)
@ar
name
Alteration of trabecular bone under chronic beta2 agonists treatment
@ast
Alteration of trabecular bone under chronic beta2 agonists treatment
@en
type
label
Alteration of trabecular bone under chronic beta2 agonists treatment
@ast
Alteration of trabecular bone under chronic beta2 agonists treatment
@en
prefLabel
Alteration of trabecular bone under chronic beta2 agonists treatment
@ast
Alteration of trabecular bone under chronic beta2 agonists treatment
@en
P2093
P3181
P1476
Alteration of trabecular bone under chronic beta2 agonists treatment
@en
P2093
Alexandre Arlettaz
Barbara Brunet-Imbault
Claude L. Benhamou
Daniel Courteix
Katia Collomp
Marie N. Horcajada
Nicolas Bonnet
P304
P3181
P356
10.1249/01.MSS.0000177592.82507.95
P577
2005-09-01T00:00:00Z